Lower FGFR2 mRNA expression and higher levels of FGFR2 IIIc in HER2-Positive breast cancer

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Dix-Peek, Thérèse
• dc.contributor.author Dickens, Caroline
• dc.contributor.author Valcárcel, J. (Juan)
• dc.contributor.author Duarte, Raquel A. B.
• dc.date.accessioned 2025-02-06T07:59:44Z
• dc.date.available 2025-02-06T07:59:44Z
• dc.date.issued 2024
• dc.description.abstract Fibroblast growth factor receptor 2 (FGFR2) has been associated with breast cancer. We performed in silico analyses to investigate the FGFR2 mRNA expression and splice variants associated with breast cancer subtypes. Online databases, including cBioPortal and TCGA SpliceSeq, were used to examine the association between the FGFR2 expression and splice variants with breast cancer subtypes. A higher FGFR2 mRNA was significantly associated with luminal, oestrogen receptor (ER)-positive breast cancers, and invasive lobular carcinomas, whereas a lower FGFR2 was associated with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and invasive ductal carcinomas. The epithelial alternatively spliced FGFR2 IIIb isoform was significantly enriched in ER+ breast cancer, while the mesenchymal FGFR2 IIIc isoform was significantly prevalent in HER2+ cancer. Increased levels of FGFR2 and IIIb splice isoforms are associated with less aggressive breast cancer phenotypes, while decreased levels of FGFR2 and increased IIIc splice isoform are associated with more aggressive phenotypes.
• dc.format.mimetype application/pdf
• dc.identifier.citation Dix-Peek T, Dickens C, Valcárcel J, Duarte RAB. Lower FGFR2 mRNA expression and higher levels of FGFR2 IIIc in HER2-Positive breast cancer. Biology (Basel). 2024 Nov 13;13(11):920. DOI: 10.3390/biology13110920
• dc.identifier.doi http://dx.doi.org/10.3390/biology13110920
• dc.identifier.issn 2079-7737
• dc.identifier.uri http://hdl.handle.net/10230/69507
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Biology (Basel). 2024 Nov 13;13(11):920
• dc.rights © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword FGFR2
• dc.subject.keyword HER2
• dc.subject.keyword IIIb
• dc.subject.keyword IIIc
• dc.subject.keyword Alternative splicing
• dc.subject.keyword Breast cancer
• dc.subject.keyword mRNA expression
• dc.title Lower FGFR2 mRNA expression and higher levels of FGFR2 IIIc in HER2-Positive breast cancer
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion